General Information of Drug (ID: DMD2BIT)

Drug Name
AT001/r84 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMD2BIT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aflibercept DMT3D5I Central retinal vein occlusion with macular edema Approved [2]
Brolucizumab DMW8QNG Wet age-related macular degeneration 9B78.3Z Approved [3]
Faricimab DM83SEB Diabetic macular edema 9B71.02 Approved [4]
Ranibizumab DMSYPNW Central retinal vein occlusion with macular edema Approved [5]
Bevacizumab DMSD1UN Adenocarcinoma 2D40 Approved [6]
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [7]
PTC299 DMP9TKE Rheumatoid arthritis FA20 Phase 2 [8]
RG7221 DM8J9DC Colorectal cancer 2B91.Z Phase 2 [9]
RO5520985 DMD3WNP Colorectal cancer 2B91.Z Phase 2 [10]
Abicipar pegol DM59OJ2 Diabetic macular edema 9B71.02 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Not Available [1]

References

1 Clinical pipeline report, company report or official report of Affitech (2011).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
5 Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
6 FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
7 Clinical pipeline report, company report or official report of Genentech (2009).
8 Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
9 Bispecific antibodies and their applications
10 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)